BMY · Bristol-Myers Squibb Company
$57.522026-07-21Sector: Healthcare; Industry: Drug Manufacturers - General; Sub-Industry: Pharmaceuticals
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Very High Uncertainty
Bull
$329
+471.7% vs market
Base · active
$81
+40.3% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($81 · $329) Analysts Range ($40 · $75) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2024.Q1 | $45.0B | — | 21.9% | 0.0% | $10.3B | −$13.9B | −$3.5B | 5.5% | — | 11.4% | $90.3B | $3.93 | — |
| 2024.Q4 | $45.0B | 0.0% | 21.9% | 0.0% | $10.5B | −$13.5B | −$3.0B | 6.1% | — | 12.1% | $82.9B | $3.93 | — |
| 2025.Q1 | $48.3B | 7.3% | 23.2% | 11.0% | $10.0B | $2.8B | $12.8B | 5.7% | — | 11.9% | $84.8B | $-4.38 | — |
| 2025.Q4 | $48.3B | 0.0% | 23.2% | 24.4% | $8.5B | −$3.5B | $5.0B | 5.3% | — | 10.1% | $82.5B | $-4.38 | — |
| 2026.Q1 | $48.5B | 0.4% | 29.8% | 24.2% | $11.0B | −$5.4B | $5.6B | 5.3% | — | 13.3% | $82.9B | $3.56 | 8.1 |
| italics below = DCF projection · 10yr Rev CAGR: 0.6% |
| 2027.Q1 | $47.1B | +-2.9% | 34.7% | 23.8% | $12.4B | $0MM | $12.4B | 5.6% | $11.8B | 15.0% | $82.9B | $4.51 | 12.8 |
| 2028.Q1 | $46.1B | +-2.1% | 34.0% | 23.4% | $12.0B | $0MM | $12.0B | 5.9% | $10.7B | 14.5% | $82.9B | $4.49 | 12.8 |
| 2029.Q1 | $45.4B | +-1.4% | 33.4% | 22.9% | $11.7B | $0MM | $11.7B | 6.2% | $9.9B | 14.1% | $82.9B | $4.50 | 12.8 |
| 2030.Q1 | $45.2B | +-0.6% | 32.8% | 22.5% | $11.5B | $0MM | $11.5B | 6.5% | $9.1B | 13.9% | $82.9B | $4.55 | 12.6 |
| 2031.Q1 | $45.3B | +0.2% | 31.6% | 22.1% | $11.1B | $0MM | $11.1B | 6.8% | $8.2B | 13.4% | $82.9B | $4.69 | 12.3 |
|
| Term. Yr+ | $53.4B | 4.1% | 31.6% | 20.0% | $13.5B | −$4.2B | $9.3B | 8.6% | $105.2B | 13.1% | — | — | — |
Active scenario IV: $81 (+40.3% vs market)